Crystal structure of anti-configuration of indomethacin and leukotriene B4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase complex reveals the structural basis of broad spectrum indomethacin efficacy

Journal of Biochemistry

Volumn 140, Issue 3, 2006, Pages 457-466

  Hori, Tetsuya ^a   Ishijima, Jun ^a   Yokomizo, Takehiko ^b,c   Ago, Hideo ^a   Shimizu, Takao ^b   Miyano, Masashi ^a  

^a Harima Institute ^*  (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Crystal structure; Indomethacin; Inhibition mechanism; Isothermal titration calorimetry; Leukotriene B4 12 hydroxydehydrogenase 15 oxo prostaglandin 13 reductase

Indexed keywords

15 OXO PROSTAGLANDIN 13 REDUCTASE; ARGININE; CARBOXYL GROUP; CHLOROBENZENE; CYCLOOXYGENASE 2; HOMODIMER; HYDROXYL GROUP; ICOSANOID; INDOMETACIN; LEUKOTRIENE B4 12 HYDROXYDEHYDROGENASE; LEUKOTRIENE B4 DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHOSPHOLIPASE A2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CALORIMETRY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG PROTEIN BINDING; ENZYME PURIFICATION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

15-OXOPROSTAGLANDIN 13-REDUCTASE; ALCOHOL OXIDOREDUCTASES; ANIMALS; CRYSTALLIZATION; CRYSTALLOGRAPHY; GUINEA PIGS; INDOMETHACIN; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; SPECTROPHOTOMETRY, ULTRAVIOLET; X-RAY DIFFRACTION;

EID: 33750682661     PISSN: 0021924X     EISSN: None     Source Type: Journal    
DOI: 10.1093/jb/mvj176     Document Type: Article

References (42)

1. Ferreira, S.H., Moncada, S., and Vane, J.R. (1971) Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New. Biol. 231, 237-239
2. Smith, W.L. and Lands, W.E. (1971) Stimulation and blockade of prostaglandin biosynthesis. J. Biol. Chem. 246, 6700-6702
3. Hla, T. and Neilson, K. (1992) Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 89, 7384-7388
4. Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E., and Koo, E.H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216
5. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., and Kliewer, S.A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410
6. Baek, S.J., Kim, K.S., Nixon, J.B., Wilson, L.C., and Eling, T.E. (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 59, 901-908
7. 4 dehydrogenase. Biochem. Biophys. Res. Commun. 288, 868-874
8. 2 11-ketoreductase activity. J. Biochem. 124, 940-946
9. Yamada, T., Komoto, J., Watanabe, K., Ohmiya, Y., and Takusagawa, F. (2005) Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2). J. Mol. Biol. 348, 1163-1176
10. Yu, K., Bayona, W., Kallen, C.B., Harding, H.P., Ravera, C.P., McMahon, G., Brown, M., and Lazar, M.A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975-23983
11. 2 receptor, CRTH2. J. Immunol. 168, 981-985
12. 4 12-hydroxydehydrogenase/15-ketoprostaglandin 13-reductase. Eur. J. Biochem. 268, 6105-6113
13. 4 12-hydroxydehydrogenase: implications for chemoprevention. Carcinogenesis 19, 999-1005
14. 4 by a novel enzyme found in the porcine kidney. J. Biol. Chem. 268, 18128-18135
15. Ensor, C.M., Zhang, H., and Tai, H.H. (1998) Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J. 330, 103-108
16. 4 metabolic inactivation. J. Biol. Chem. 275, 25372-25380
17. 4 12-hydroxydehydrogenase/15-oxo-prostaglandin 13-reductase catalytic mechanism and a possible Src homology 3 domain binding loop. J. Biol. Chem. 279, 22615-22623
18. Lawrence, T., Willoughby, D.A., and Gilroy, D.W. (2002) Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. 2, 787-795
19. 4 receptors. Prostaglandins Other Lipid Mediat. 68-69, 575-585
20. Charlier, C. and Michaux, C. (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 38, 645-659
21. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., and Serhan, C.N. (2001) Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2, 612-619
22. Kumasaka, T., Yamamoto, M., Yamashita, E., Moriyama, H., and Ueki, T. (2002) Trichromatic concept optimizes MAD experiments in synchrotron X-ray crystallography. Structure 10, 1205-1210
23. Otwinowski, Z. and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326
24. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T., and Warren, G.L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. Sect. D 54, 905-921
25. Loll, P.J., Garavito, R.M., Carrell, C.J., and Carrell, H.L. (1996) 1-(4-iodobenzoyl)-5-methoxy-2-methyl-3-indoleacetic acid, an iodinated indomethacin analog. Acta. Crystallogr. Sect. C 52, 455-157
26. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. Sect. A 47, 110-119
27. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 53, 240-255
28. Kraulis, P.J. (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950
29. Esnouf, R.M. (1997) An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. 15, 132-134
30. Merrit, E.A. and Bacon, D.J. (1997) Raster 3D: Photorealistic molecular graphics. Methods Enzymol. 277, 505-524
31. Burley, S.K. and Petsko, G.A. (1986) Dimerization energetics of benzene and aromatic amino acid side chains. J. Am. Chem. Soc. 108, 7995-8001
32. Steiner, T. (1997) Unrolling the hydrogen bond properties of C-H⋯O interactions. Chem. Commun. 727-734
33. Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K., Isakson, P.C., and Stallings, W.C. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384, 644-648
34. 2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res. 64, 1802-1810
35. Kiefer, J.R., Pawlitz, J.L., Moreland, K.T., Stegeman, R.A., Hood, W.F., Gierse, J.K., Stevens, A.M., Goodwin, D.C., Rowlinson, S.W., Marnett, L.J., Stallings, W.O., and Kurumbail, R.G. (2000) Structural insights into the stereochemistry of the cyclooxygenase reaction. Nature 405, 97-101
36. Callan, O.K., So, O.Y., and Swinney, D.C. (1996) The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem. 271, 3548-3554
37. Mancini, J.A., Riendeau, D., Falgueyret, J.P., Vickers, P.J., and O'Neill, G.P. (1995) Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal antiinflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 270, 29372-29377
38. Rowlinson, S.W., Kiefer, J.R., Prusakiewicz, J.J., Pawlitz, J.L., Kozak, K.R., Kalgutkar, A.S., Stallings, W.C., Kurumbail, R.G., and Marnett, L.J. (2003) A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J. Biol. Chem. 278, 45763-45769
39. Kalgutkar, A.S., Crews, B.C., Rowlinson, S.W., Marnett, A.B., Kozak, K.R., Remmel, R.P., and Marnett, L.J. (2000) Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc. Natl. Acad. Sci. USA 97, 925-930
40. Komoto, J., Yamada, T., Watanabe, K., and Takusagawa, F. (2004) Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43, 2188-2198
41. Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C.T., Scozzafava, A., and Klebe, G. (2004) Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47, 550-557
42. Chen, X., Morris, K.R., Griesser, U.J., Byrn, S.R., and Stowell, J.G. (2002) Reactivity differences of indomethacin solid forms with ammonia gas. J. Am. Chem. Soc. 124, 15012-15019